KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods (2017 - 2021)

Aquestive Therapeutics has reported Finished Goods over the past 5 years, most recently at $1.0 million for Q1 2021.

  • For Q1 2021, Finished Goods rose 42.8% year-over-year to $1.0 million; the TTM value through Mar 2021 reached $1.0 million, up 42.8%, while the annual FY2020 figure was $544000.0, 4.82% up from the prior year.
  • Finished Goods for Q1 2021 was $1.0 million at Aquestive Therapeutics, up from $544000.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $1.3 million in Q2 2018 and troughed at $519000.0 in Q4 2019.
  • A 5-year average of $958461.5 and a median of $1.0 million in 2019 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: tumbled 56.13% in 2019 and later surged 42.8% in 2021.
  • Year by year, Finished Goods stood at $1.1 million in 2017, then increased by 11.18% to $1.2 million in 2018, then tumbled by 56.13% to $519000.0 in 2019, then grew by 4.82% to $544000.0 in 2020, then skyrocketed by 84.01% to $1.0 million in 2021.
  • Business Quant data shows Finished Goods for AQST at $1.0 million in Q1 2021, $544000.0 in Q4 2020, and $858000.0 in Q3 2020.